Squarepoint
SGMT icon

Squarepoint’s Sagimet Biosciences SGMT Stock Holding History

Squarepoint’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$620K Buy
118,620
+33,887
+40% +$189K ﹤0.01% 3167
2025
Q4 		$502K Buy
84,733
+49,668
+142% +$357K ﹤0.01% 3219
2025
Q3 		$241K Buy
+35,065
New +$284K ﹤0.01% 3819
2025
Q1 		– Sell
-50,484
Closed -$227K – 5323
2024
Q4 		$227K Buy
50,484
+21,195
+72% +$107K ﹤0.01% 4373
2024
Q3 		$81.1K Sell
29,289
-65,451
-69% -$202K ﹤0.01% 3913
2024
Q2 		$324K Buy
+94,740
New +$435K ﹤0.01% 3387
2023
Q4 		– Sell
-35,000
Closed -$308K – 4450
2023
Q3 		$308K Buy
+35,000
New +$466K ﹤0.01% 3139

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Squarepoint's SGMT Position: Q1 2026 in Review

Squarepoint increased its Sagimet Biosciences (SGMT) stake by 40% in Q1 2026, buying an estimated $189K and bringing the position to 118,620 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

Squarepoint first reported a position in SGMT in Q3 2023 and has held it in 7 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Squarepoint held 118,620 shares of Sagimet Biosciences worth $620K as of Q1 2026.
  • Squarepoint bought 33,887 Sagimet Biosciences shares in Q1 2026, an estimated $189K.
  • Sagimet Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3167 holding.
  • Squarepoint first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 7 quarters since.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.